Evidence map›Paper›PMID 33856764›Full record

ArticleACS chemical neuroscience2021

"Photo-Rimonabant": Synthesis and Biological Evaluation of Novel Photoswitchable Molecules Derived from Rimonabant Lead to a Highly Selective and Nanomolar "

Diego A Rodríguez-Soacha, Julia Fender, Yesid A Ramírez, Juan Antonio Collado, Eduardo Muñoz, Rangan Maitra, Christoph Sotriffer, Kristina Lorenz, Michael Decker

Open access · greenAbstract read
In one paragraph

Article in ACS chemical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Investigation on NovelMolecules (Basel, Switzerland) · 2023
    Article
  6. Article
  7. Article
  8. Enlightening the "Spirit Molecule": Photomodulation of the 5-HTAngewandte Chemie (International ed. in English) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 4 countries.

Diego A Rodríguez-SoachaPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany.
Julia FenderInstitut für Pharmakologie und Toxikologie, Julius-Maximilians-Universität Würzburg, Versbacher Straße 9, D-97078 Würzburg, Germany.
Yesid A RamírezPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany.
Juan Antonio ColladoInstituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Hospital Universitario Reina Sofía, Avda Menendez Pidal s/n, 14004 Córdoba, Spain.
Eduardo MuñozInstituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Hospital Universitario Reina Sofía, Avda Menendez Pidal s/n, 14004 Córdoba, Spain.
Rangan MaitraDiscovery Science and Technology, RTI International, 3040 Cornwallis Road, Research Triangle Park, North Carolina 27709-2194, United States.ORCID 0000-0001-6663-6800
Christoph SotrifferPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany.
Kristina LorenzInstitut für Pharmakologie und Toxikologie, Julius-Maximilians-Universität Würzburg, Versbacher Straße 9, D-97078 Würzburg, Germany.
Michael DeckerPharmazeutische und Medizinische Chemie, Institut für Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany.ORCID 0000-0002-6773-6245
University of Würzburg · DEInstituto Maimónides de Investigación Biomédica de Córdoba · ESRTI International · US

Funding

APJ receptor agonism for metabolic syndrome R01DK103625 · NIDDK · RESEARCH TRIANGLE INSTITUTE · PI MAITRA, RANGAN · 2017 to 2021
$2.4M
Peripheralized CB1 antagonists for ALDR01AA022235 · NIAAA · RESEARCH TRIANGLE INSTITUTE · PI MAITRA, RANGAN · 2014 to 2018
$2.2M
Novel therapeutic approach for NASHR01DK124615 · NIDDK · RESEARCH TRIANGLE INSTITUTE · PI MAITRA, RANGAN · 2020 to 2023
$2.1M
Therapeutics Development for Hepatic FibrosisR01DK100414 · NIDDK · RESEARCH TRIANGLE INSTITUTE · PI MAITRA, RANGAN · 2014 to 2017
$1.8M
Strategy for synthetic cannabinoid abuse and toxicityU18DA052495 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI MAITRA, RANGAN · 2020 to 2020
$353k
NIAAA NIH HHS R01 AA022235NIDA NIH HHS U18 DA052495NIDDK NIH HHS R01 DK100414NIDDK NIH HHS R01 DK103625NIDDK NIH HHS R01 DK124615
6 · The paper itself

Abstract

Human cannabinoid receptor type 1 (

Indexed as

Cannabinoid Receptor AntagonistsReceptor, Cannabinoid, CB1HumansMolecular Docking SimulationRimonabantCannabinoid Receptor AntagonistsReceptor, Cannabinoid, CB1Rimonabantazo-extensionazologizationcannabinoid receptorG-protein-coupled receptorphotochromic moleculesPhotopharmacology

Identifiers

PMID33856764
PMCPMC9016771
OpenAlexW3154943790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.